Select Format:

Select Volume:




Cat. No.




Enhancer of Zeste Homolog 2 (EZH2) is a methylase of histone H3 that silences gene expression in those regions. EZH2 is overexpressed or mutated in gastric, prostate, uterine, breast, and renal cell cancers, as well as in melanoma and most B- and T-lymphocyte lymphomas. Although EZH2 is usually present in follicular centers, it is not expressed in the mantle zones, plasma cells, follicular or interfollicular T-lymphocytes, natural killer T-lymphocytes, plasmacytoma, lymphoplasmacytic lymphoma, or MALT lymphoma. EZH2 is rarely present in normal breast duct epithelium and in normal and hyperplastic lymph node. Anti-EZH2 is also useful for detecting lymphoma and non-small cell lung cancers. EZH2 is associated with tumor proliferation and can be used in staining panels to distinguish aggressive lymphomas from less aggressive lymphomas or normal cells.
  • References
    1. Ciarapica R, et al. BMC Med. 2011; 9:63.
    2. Abd Al Kader L, et al. Virchows Arch. 2013; 463:697-711.
    3. Varambally S, et al. Nature. 2002; 419:624-9.
    4. Tan JZ, et al. Acta Pharmacol Sin. 2014; 35:161-74.


Clone IHC570
Source Mouse Monoclonal
Positive Control Prostate Adenocarcinoma, Tonsil, Breast Carcinoma
Dilution Range 1:50-1:200